Cargando…
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma
The increasing importance of hypoxia-inducible factor-1α (HIF-1α) in tumorigenesis raises the possibility that agents which specifically inhibit this transcription factor, would provide significant therapeutic benefit. The constitutive expression of HIF-1α in about 35% of Multiple Myeloma (MM) patie...
Autores principales: | Borsi, Enrica, Perrone, Giulia, Terragna, Carolina, Martello, Marina, Dico, Angela F., Solaini, Giancarlo, Baracca, Alessandra, Sgarbi, Gianluca, Pasquinelli, Gianandrea, Valente, Sabrina, Zamagni, Elena, Tacchetti, Paola, Martinelli, Giovanni, Cavo, Michele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039126/ https://www.ncbi.nlm.nih.gov/pubmed/24732040 |
Ejemplares similares
-
Hypoxia and IF(1) Expression Promote ROS Decrease in Cancer Cells
por: Sgarbi, Gianluca, et al.
Publicado: (2018) -
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
por: Martello, M., et al.
Publicado: (2022) -
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
por: Terragna, Carolina, et al.
Publicado: (2015) -
Cap dependent translation contributes to resistance of myeloma cells to bortezomib
por: Mancino, Marilena, et al.
Publicado: (2013) -
Front-line treatment of multiple myeloma
por: Cavo, Michele, et al.
Publicado: (2019)